Log in to save to my catalogue

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine...

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_03ee2b06a3cf4b8ba50f0091731a8e25

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

About this item

Full title

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

Publisher

England: BioMed Central Ltd

Journal title

BMC nephrology, 2018-09, Vol.19 (1), p.237-237, Article 237

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Conversion from calcineurin inhibitor (CNI) therapy to a mammalian target of rapamycin (mTOR) inhibitor following kidney transplantation may help to preserve graft function. Data are sparse, however, concerning the impact of conversion on posttransplant diabetes mellitus (PTDM) or the progression of pre-existing diabetes.
PTDM and other diabetes...

Alternative Titles

Full title

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_03ee2b06a3cf4b8ba50f0091731a8e25

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_03ee2b06a3cf4b8ba50f0091731a8e25

Other Identifiers

ISSN

1471-2369

E-ISSN

1471-2369

DOI

10.1186/s12882-018-1031-1

How to access this item